Italia markets open in 6 hours 20 minutes

Incyte Corporation (INCY)

NasdaqGS - NasdaqGS Prezzo in tempo reale. Valuta in USD.
Aggiungi a watchlist
52,72-0,50 (-0,94%)
Alla chiusura: 04:00PM EDT
52,69 -0,03 (-0,06%)
Dopo ore: 04:24PM EDT
Schermo intero
I prezzi di scambio non provengono da tutti i mercati
Chiusura precedente53,22
Aperto53,22
Denaro52,70 x 100
Lettera52,73 x 100
Min-Max giorno52,70 - 53,78
Intervallo di 52 settimane50,27 - 75,74
Volume2.454.796
Media Volume1.670.303
Capitalizzazione11,837B
Beta (5 anni mensile)0,67
Rapporto PE (ttm)19,89
EPS (ttm)2,65
Prossima data utili30 apr 2024
Rendimento e dividendo (futuro)N/D (N/D)
Data ex dividendoN/D
Stima target 1A75,35
  • GlobeNewswire

    Global CAR T-cell Therapy Market Projected to Reach $83 Billion by 2032

    PALM BEACH, Fla., Oct. 12, 2023 (GLOBE NEWSWIRE) -- FinancialNewsMedia.com News Commentary - Significant influences driving the CAR T-cell therapy market is a rising demand for model therapeutics for treatment of cancer, increase in prevalence of cancer and an escalating awareness of CAR T-cell therapy medicines. The CAR T-cell therapy market is currently going through a rapid expansion, owing to rapidly expanding clinical trial activities and recent commercialization of CAR-T cell therapy, whic

  • GlobeNewswire

    Knight Therapeutics Announces Regulatory Submission of Pemigatinib in Brazil

    MONTREAL, Oct. 10, 2023 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-USA) specialty pharmaceutical company, announced today that its Brazilian affiliate, United Medical Ltd., has submitted a marketing authorization application for pemigatinib to ANVISA, the Brazilian health regulatory agency, under the rare diseases approval pathway, for the treatment of adults with locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor recepto